US Patent 5,795,911: Scope, Claim Boundaries, and US Landscape for Tea-Catechin Treatment of HPV-Related Condyloma
What does US 5,795,911 claim cover?
US 5,795,911 claims a method of treating condyloma acuminata caused by human papillomavirus (HPV) by applying a composition whose main component is “tea catechin” in an amount effective to treat the condition. The independent concept is narrow in disease etiology (HPV-related condyloma) and narrow in active identity (tea catechin as the main component), while dependent claims narrow form factor (ointment or suppository) and quantitative composition (weight %, capsule content) and site of administration.
Claim set (as provided)
- Claim 1 (independent): Treat condyloma acuminata caused by HPV by applying to an infected area a composition comprising tea catechin as a main component in an amount effective for treatment.
- Claim 2: Composition form is ointment or suppository.
- Claims 3, 6–11: Ointment specifics
- Claim 3: Ointment has 5–20 wt% tea catechin.
- Claim 6: Tea catechin is 12–18 wt%.
- Claim 10: Vaseline base.
- Claim 11: Applied to external genital organs.
- Claims 4, 7–9, 12: Suppository specifics
- Claim 4: Suppository has 100–500 mg tea catechin per capsule.
- Claim 7: Tea catechin 15 wt%.
- Claim 8: Capsule contains 200–300 mg tea catechin.
- Claim 9: Capsule contains 250 mg tea catechin.
- Claim 12: Applied to the vagina.
- Claims 5, 13–15: Active ingredient identity and anatomical targets
- Claim 5: Tea catechin comprises (-)-epigallocatechin.
- Claim 13: Infected area is vagina.
- Claim 14: Infected area is external genital organ.
- Claim 15: Infected area is cervix.
How is the claim scope technically constrained?
1) The method is “treating HPV-CA” with “tea catechin as main component”
The core infringement trigger is both:
- Disease state: condyloma acuminata caused by HPV.
- Act of application: apply a composition to an infected area that has tea catechin as the main component.
This matters because many topical “green tea extract” products contain catechins but do not frame the active as “tea catechin” or do not position tea catechins as the main component. The phrase “as a main component” is a material boundary that pushes the analysis toward relative formulation composition (dominance of tea catechin among actives) rather than incidental presence.
2) The anatomical scope spans multiple genital sites
Claims expressly cover:
- Vagina (Claims 12 and 13)
- External genital organs (Claims 11 and 14)
- Cervix (Claim 15)
That triad expands potential infringement reach beyond a single route/site, which affects product development paths (form factor and placement).
3) The dependent claims impose hard numerical thresholds
For ointment:
- 5–20 wt% tea catechin (Claim 3)
- narrower band 12–18 wt% (Claim 6)
- specific band vaseline base (Claim 10)
For suppository:
- 100–500 mg tea catechin per capsule (Claim 4)
- narrower capsule content 200–300 mg (Claim 8)
- further single-point claim 250 mg (Claim 9)
These bands function as “claim islands”: designs outside the numeric windows reduce risk for those dependent claim theories, though they can still fall back on Claim 1 if “amount effective” and “main component” are satisfied.
4) Active definition includes (-)-epigallocatechin
Claim 5 requires tea catechin to comprise (-)-epigallocatechin. Practically, this is a meaningful narrowing step because “tea catechin” can be a broader mixture. The claim language ties the ingredient set to epigallocatechin presence.
What product designs fall inside vs outside the claim risk perimeter?
The claim set supports three main “risk tiers” for a competitor’s R&D program.
Tier A: Direct cover under Claim 1 (broadest)
Potentially within scope if all conditions are met:
- topical treatment for HPV-CA
- application to covered sites (vagina, external genital organs, cervix)
- formulation where tea catechin is the main component
- administration is done as a treating method
Risk stays even if the product is not an ointment or suppository, because Claim 1 requires a composition, not a specific dosage form (Claim 2 adds dosage form limits as dependent coverage).
Tier B: Direct cover under dependent claims (numerical/formulation/site)
Risk rises sharply if the product is:
- an ointment with 5–20 wt% tea catechin (Claim 3)
- especially 12–18 wt% (Claim 6)
- with vaseline base (Claim 10)
- or a suppository with 100–500 mg tea catechin per capsule (Claim 4)
- with 200–300 mg (Claim 8)
- at/near 250 mg (Claim 9)
- administered vaginally (Claim 12)
Tier C: Likely outside dependent claims, but still vulnerable to Claim 1
A product may avoid dependent claim numbers by reformulating, for example:
- ointment with tea catechin outside 5–20 wt%, or
- suppository capsule content outside 100–500 mg
- omit vaseline base
- use administration route outside vagina/external/cervix (though Claim 1 still requires the “infected area” concept tied to those targets through dependent coverage)
Even then, if the product still meets Claim 1’s “tea catechin main component” and “amount effective” in HPV-CA treatment, Claim 1 exposure remains.
What are the claim construction pressure points likely to matter in litigation?
Without prosecution history, the best read comes from the text you provided:
1) “Tea catechin as a main component”
Key issue is whether “main component” is measured by:
- weight fraction,
- active fraction relative to other components (excipients vs actives),
- or dominance among “actives” rather than total formulation.
For business strategy, the practical consequence is that products using low-dose catechin blends or products where other botanical actives are present at higher proportions should be treated as lower-probability matches to Claim 1, unless tea catechin remains dominant.
2) “Tea catechin comprises (-)-epigallocatechin”
If a formulation uses other catechins but excludes epigallocatechin, it should reduce fit to Claim 5-dependent theories. But it may not eliminate Claim 1 if Claim 1 does not require epigallocatechin specifically (it does not, per the provided text).
3) “Amount effective”
This is a classic functional limitation. Dependent claims add fixed numeric compositions, but Claim 1 allows a broader range anchored to effectiveness. For infringement analysis, “amount effective” is typically proved through:
- clinical outcome,
- pharmacology/efficacy data,
- or formulation guidance showing effective dosing.
From a product standpoint, staying outside dependent numeric ranges is not a guaranteed safety measure if the dose is still “effective” and tea catechin is “main component.”
4) Anatomical “infected area”
Dependent claims specify sites. If the product is administered to a site not listed in the dependent claims, Claim 1 still stays tied to “infected area” but the disease is specified as condyloma acuminata (HPV). The strongest fit remains when the infected area corresponds to vagina, external genital organs, or cervix.
What is the likely patent landscape shape in the US?
Given only the claims of US 5,795,911 (and not the full family data, specification, priority, or cited references), the most defensible landscape characterization is structural: a narrow, formulation-and-method claim around tea catechins for HPV condyloma.
Landscape implications for competitors
- Botanical extract entrants face a higher risk of inheriting scope from “tea catechin as main component” if they market and instruct use for HPV condyloma and apply to the covered genital sites.
- Controlled-dose formulators can reduce dependent claim fit by moving outside the numeric windows. The remaining risk is still Claim 1 exposure if efficacy and “main component” align.
- Compound-specific eliminators can reduce Claim 5 risk by excluding (-)-epigallocatechin, while still possibly remaining exposed under Claim 1 if “tea catechin” in general remains the main component.
- Route and dosage form changes may reduce dependent claim fit (ointment vs suppository; vaseline base; vaginal suppository) but may not remove independent Claim 1 exposure.
Business takeaway from the scope
The claim set is a dosage-form-and-dose-banded method patent for topical treatment of HPV-CA using tea catechins. That tends to create a landscape where:
- infringement theories focus on clinical instructions and formulation composition, not just chemical identity; and
- design-arounds revolve around catechin concentration, dosage format, base/excipient choices, and administration instructions.
Where are the hardest “design-around” traps?
Even without numeric confirmation beyond the provided text, the claim structure creates three trap zones:
-
Maintaining “tea catechin as main component”
- If tea catechin remains dominant among actives, most design variations will still land in Claim 1.
-
Staying effective for HPV condyloma
- If clinical outcomes show treatment efficacy at topical sites for HPV-CA, “amount effective” can be argued broadly.
-
Covering genital sites
- Claims explicitly name vagina, external genital organs, and cervix. In practice, many HPV-CA topical regimens target these sites, limiting freedom to avoid dependent claim theories.
What does this mean for enforcement leverage and settlement posture?
A competitor challenging infringement would typically concentrate arguments on:
- whether tea catechin is the “main component” in the applied composition,
- whether (-)-epigallocatechin is present (for Claim 5-dependent theories),
- whether formulation concentrations match the dependent bands,
- whether product instructions target the covered infected areas.
Meanwhile, the patent owner’s leverage rests on:
- the specificity of anatomical targets,
- the presence of fixed concentration and dosage bands in dependent claims,
- and the direct linkage to HPV-related condyloma treatment through a topical method.
Key Takeaways
- US 5,795,911 covers topical treatment methods for HPV-caused condyloma acuminata using a composition where tea catechin is the main component.
- Dependent claims materially narrow into ointment formulations (5–20 wt%, with narrower 12–18 wt%, and vaseline base) and suppositories (100–500 mg per capsule, with 200–300 mg and a specific 250 mg content).
- The claim set also specifies active composition with (-)-epigallocatechin and explicitly covers infected areas including the vagina, external genital organs, and the cervix.
- For landscape and R&D planning, the most consequential decision points are catechin dominance (main component), dose placement relative to numeric bands, whether (-)-epigallocatechin is included, and where and how the product is applied.
FAQs
-
Does Claim 1 require an ointment or suppository?
No. Claim 1 requires a method applying a composition with tea catechin as the main component in an effective amount; dosage form is specified only in dependent Claim 2.
-
What ointment concentrations are explicitly claimed?
The ointment has 5–20 wt% tea catechin (Claim 3), with a narrower band of 12–18 wt% (Claim 6).
-
What suppository dose ranges are explicitly claimed?
The capsule contains 100–500 mg tea catechin (Claim 4), with 200–300 mg (Claim 8) and a specific 250 mg embodiment (Claim 9).
-
Is (-)-epigallocatechin mandatory for infringement?
It is required for the scope of Claim 5-dependent coverage (“tea catechin comprises (-)-epigallocatechin”). Claim 1, as provided, does not explicitly require epigallocatechin.
-
Which anatomical sites are explicitly covered?
Vagina (Claims 12 and 13), external genital organs (Claims 11 and 14), and cervix (Claim 15).
References
[1] United States Patent 5,795,911. Claims as provided by user (tea catechin topical treatment of HPV-related condyloma acuminata).
